943 drugs approved. $15M to $100M in development costs versus $2.6B for an NCE. One regulatory mechanism sits at the […]
505(b)(2) NDAs: The Complete IP, Litigation, and Commercial Strategy Guide for 2025 Read Post »
1. What Pharmaceutical Sales Data Actually Measures Pharmaceutical sales data is not a single dataset. It is a composite of
Drug Sales Data: The Complete Playbook for Channel Strategy and Portfolio Dominance Read Post »
How to use price erosion curves, Paragraph IV filings, Orange Book patent analysis, and biosimilar IP valuation to build a
Generic Entry Pricing: The Complete Drug Price Data Playbook for Portfolio Managers Read Post »
Generic drugs account for nearly 90% of all prescriptions dispensed in the United States yet represent only about 20% of
DrugPatentWatch, a provider of global biopharmaceutical business intelligence, has entered into a partnership with Adis. The partner will enhance Adis’
DrugPatentWatch Partners with Adis: Helping Drug Companies Make Better Decisions Read Post »
Branded generics are generic drugs that have been given proprietary brand names. They have a small, but profitable place in the U.S. pharmaceutical market.
Branded Generics and Why They’re Profitable Read Post »
Pre-ANDA Litigation Strategy: The Complete Playbook for Building Unbreakable Drug Patent Portfolios For IP counsel, portfolio managers, R&D leads, and
Pharmaceutical life cycle management begins earlier and ends later to maximize stakeholder value in all phases of drug development.
For readers following the the Biologic Patent Transparency Act, DrugPatentWatch has recently been cited in an article describing the act as
DrugPatentWatch in the news: The Biologic Patent Transparency Act. Read Post »
Sign in or create a free account to read this DrugPatentWatch article
